Clinical Trial Update: 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients

View source ↗

Summary

A clinical trial is evaluating the PET tracer 18F-FAPI-74 for imaging in patients with pulmonary tuberculosis. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Tuberculosis
• Tuberculosis

Drugs mentioned

• [18F] FAPI-74 (Fluorine-18 labeled fibroblast activation protein inhibitor FAPI-74)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Tuberculosis, Pulmonary | Status: RECRUITING